Introduction Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.
State of the Industry 2019:
KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables.
The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.
214 clinical trials professionals from within pharma and biotech (28%), CROs (29%), service providers, consultancies and medical device companies (26%), investigator sites (6%) and academia (4%) responded to the survey. The majority of respondents were from Europe (66%) followed by North America (17%) and Asia (13%).
In 2017, Informa Pharma Intelligence took a deep dive into the clinical trial landscape in China over the previous 10 years, in a whitepaper entitled “Is China the Dark Horse in Clinical Development?”. That analysis showed that the number of trial starts in China had been trending upwards year-on-year and suggested that China was on course to become a formidable player within the pharma industry on a global stage.
Topics Clinical Trials
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: